Targeted Drug Delivery Systems for Pancreatic Cancer

被引：34
作者：
Khare, Vaibhav [1 ]
Alam, Noor [1 ]
Saneja, Ankit [1 ]
Dubey, Ravindra Dhar [1 ]
Gupta, Prem N. [1 ]
机构：
[1] CSIR, Indian Inst Integrat Med, Formulat & Drug Delivery Div, Jammu 180001, India
来源：
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY | 2014年 / 10卷 / 12期
关键词：
Pancreatic Cancer; Targeted Drug Delivery; Nanomedicine; Novel Drug Delivery Systems; Ligand; Nanoparticles; ENDOTHELIAL GROWTH-FACTOR; TUMOR-SUPPRESSOR GENE; PEGYLATED-LIPOSOMAL DOXORUBICIN; INTERSTITIAL FLUID PRESSURE; PHASE-I; TRANSFERRIN RECEPTOR; POLYMERIC MICELLES; HYALURONIC-ACID; QUANTUM DOTS; DUCTAL ADENOCARCINOMA;
D O I：
10.1166/jbn.2014.2036
中图分类号：
TB3 [工程材料学];
学科分类号：
0805 ; 080502 ;
摘要：
Pancreatic cancer is usually diagnosed at the advanced stages, responds poorly to the available chemotherapeutics and constitutes the major factor for high mortality rate. Selective delivery of therapeutics to their cellular targets, without side effects is the foremost objective of the current investigations for effective treatment of pancreatic cancer. The development of the drugs which can selectively target pancreatic cancer along with carriers that can deliver drugs specifically to the rapidly dividing cells is considered as magic bullet for the efficient treatment of this fatal disease. This review describes various factors hampering the efficacy of drug targeting to pancreatic cancer including stromal fortress, hypocascularity, hyaluronan and interstitial fluid pressure, and exploration of various cellular targets for the site specific drug delivery. An account of burgeoning applications of novel drug delivery systems including nanoparticles, liposomes, quantum dots, micelles and drug conjugates in the management of pancreatic cancer is also provided. Additionally, potential of target based therapeutic agents and nanomedicines in clinical trials for the pancreatic cancer therapy are highlighted.
引用
收藏
页码：3462 / 3482
页数：21
相关论文
共 230 条
  • [1] Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine
    Abou-Alfa, Ghassan K.
    Chapman, Paul B.
    Feilchenfeldt, Jonas
    Brennan, Murray F.
    Capanu, Marinela
    Gansukh, Bolorsukh
    Jacobs, Gria
    Levin, Adrah
    Neville, Deirdre
    Kelsen, David P.
    O'Reilly, Eileen M.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (03): : 321 - 325
  • [2] EGFR Targeted PLGA Nanoparticles Using Gemcitabine for Treatment of Pancreatic Cancer
    Aggarwal, Sahil
    Yadav, Sachin
    Gupta, Swati
    [J]. JOURNAL OF BIOMEDICAL NANOTECHNOLOGY, 2011, 7 (01) : 137 - 138
  • [3] The use of nanocrystals in biological detection
    Alivisatos, P
    [J]. NATURE BIOTECHNOLOGY, 2004, 22 (01) : 47 - 52
  • [4] Allison DC, 1998, J SURG ONCOL, V67, P151, DOI 10.1002/(SICI)1096-9098(199803)67:3<151::AID-JSO2>3.3.CO
  • [5] 2-4
  • [6] Defining New Paradigms for the Treatment of Pancreatic Cancer
    Almhanna, Khaldoun
    Philip, Philip A.
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2011, 12 (02) : 111 - 125
  • [7] [Anonymous], 2013, Cancer Discov, V3, pOF1, DOI 10.1158/2159-8290.CD-NB2013-160
  • [8] Hyaluronic acid-coated liposomes for active targeting of gemcitabine
    Arpicco, Silvia
    Lerda, Carlotta
    Pozza, Elisa Dalla
    Costanzo, Chiara
    Tsapis, Nicolas
    Stella, Barbara
    Donadelli, Massimo
    Dando, Ilaria
    Fattal, Elias
    Cattel, Luigi
    Palmieri, Marta
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2013, 85 (03) : 373 - 380
  • [9] Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy
    Arya, Geetanjali
    Vandana, Mallaredy
    Acharya, Sarbari
    Sahoo, Sanjeeb K.
    [J]. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2011, 7 (06) : 859 - 870
  • [10] Assmann V, 1996, CLIN CANCER RES, V2, P1607
12345678910